KRAS mutation, for instance, in colorectal cancer induces the expression of immune mediators such as the cytokine granulocyte macrophage-colony stimulating factor (GM-CSF), which acts as a strong immunosuppressive factor [11,12]. This evidence concerns the gene CSF2 and colorectal cancer.